Atypical Antidepressant
Tianeptine
A compound that acts on the brain's glutamate signalling to influence mood and thinking.
KÖGN Health grades Tianeptine as B+ (Moderate evidence) and rates it 4.0 out of 5.
Last reviewed · June 2026
Primary effects
- Mood improvement
- Stress reduction
- Cognitive support
How it works
Regulates glutamate signalling and supports mood and stress response systems.
Overview
Tianeptine is an atypical compound with antidepressant properties that also influences glutamatergic activity in the brain. It has been studied for its effects on mood, anxiety, and cognitive function. However, it carries a significant risk of dependence and misuse potential, which limits its suitability as a general nootropic. Its use should be approached with caution.
The evidence
Tianeptine is a prescription antidepressant in parts of Europe and Asia with an unusual mechanism — it is a mu-opioid receptor agonist. At therapeutic doses it treats depression, but it is included here mainly as a warning: sold unregulated as 'gas station heroin' (ZaZa, Tianna Red), it is widely misused at many times the therapeutic dose, with rapid tolerance and opioid-like dependence.
Safety & side effects
At high or escalating doses it produces opioid-like effects, dependence, and a withdrawal syndrome; overdose and abuse cases — sometimes requiring buprenorphine to manage — are rising. It is not a benign nootropic.
Who should avoid it
Prescription-only where it is licensed at all, and banned or controlled in a growing number of US states. It should not be self-sourced or used as a nootropic; it interacts dangerously with opioids and other CNS depressants. If you are using it, seek medical support rather than stopping abruptly.
References
Related ingredients
Graded entries that target the same cognitive goals.
Categories
Draft — the dose, safety and evidence notes on this entry were prepared from the published literature and are pending editorial and clinical review.
Educational information, not medical advice. The evidence grade is KÖGN’s editorial assessment of published research, not a health claim. Speak to a qualified clinician before changing what you take.